what is your take on the lower occurrence of adverse events during clinical trials of second generation antisense drugs versus rnai. the single strand rna appears to possess the ability to use at higher doses than normal rnai drugs without as many harmful side effects. I guess well find out after the 1103 dose escillation study. but this appears to be the case.
- Forums
- ASX - By Stock
- Ann: Placement and Share Purchase Plan
what is your take on the lower occurrence of adverse events...
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
|
|||||
Last
8.2¢ |
Change
0.002(2.50%) |
Mkt cap ! $73.92M |
Open | High | Low | Value | Volume |
8.1¢ | 8.5¢ | 8.1¢ | $145.4K | 1.739M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 69272 | 8.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.4¢ | 71037 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 69272 | 0.082 |
1 | 149432 | 0.081 |
2 | 127625 | 0.080 |
1 | 3600 | 0.079 |
2 | 250000 | 0.078 |
Price($) | Vol. | No. |
---|---|---|
0.084 | 71037 | 1 |
0.086 | 480000 | 3 |
0.087 | 400000 | 1 |
0.088 | 417000 | 3 |
0.089 | 228000 | 3 |
Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online